ImmuCell (ImmuCell) Change In Working Capital : $-0.76 Mil (TTM As of Mar. 2024)

View and export this data going back to 1995. Start your Free Trial

What is ImmuCell Change In Working Capital?

ImmuCell's change in working capital for the quarter that ended in Mar. 2024 was $0.14 Mil.

ImmuCell's change in working capital for the fiscal year that ended in Dec. 2023 was $-2.11 Mil.

It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement. Not by calculating the number changes in each periods' working capital (Total Current Assets minus Total Current Liabilities).

ImmuCell Change In Working Capital Historical Data

The historical data trend for ImmuCell's Change In Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ImmuCell Change In Working Capital Chart

ImmuCell Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Working Capital

Get a 7-Day Free Trial

-1.10

0.53

-1.62

-1.83

-2.11

ImmuCell Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Change In Working Capital	Get a 7-Day Free Trial															-1.22	-0.08	-0.44	-0.37	0.14

ImmuCell Change In Working Capital Calculation

Change In Working Capital for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.76 Mil.

Working Capital is a measure of a company's short term liquidity or its ability to cover short term liabilities. It is defined as the difference between a company's current assets and current liabilities.

Changes in Working Capital is reported in the cash flow statement since it is one of the major ways in which net income can differ from operating cash flow. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement.

Use Wal-Mart Stores Inc (Jan 2014, Annual Data) as an example: Source: Wal-Mart Stores Inc 2014-01-31 10-K from SEC

Consolidated Statements of Cash Flows	Fiscal Years Ended	January 31,	(Amounts in millions)
Cash flows from operating activities:	2014	2013	2012
Changes in certain assets and liabilities, net of effects of acquisitions:
Receivables, net	(566)	(614)	(796)
Inventories	(1,667)	(2,759)	(3,727)
Accounts payable	531	1,061	2,687
Accrued liabilities	103	271	(935)
Accrued income taxes	(1,224)	981	994

For 2014-01-31, add all the items under 2014 collum together, Change in Working Capital was (566) + (1,667) + 531 + 103 + (1,224) = $ (2,823) Mil.

ImmuCell Change In Working Capital Related Terms

Thank you for viewing the detailed overview of ImmuCell's Change In Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

ImmuCell (ImmuCell) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ImmuCell Corp (NAS:ICCC) » Definitions » Change In Working Capital

Comparable Companies

Traded in Other Exchanges

IUL:Germany

Address

56 Evergreen Drive, Portland, ME, USA, 04103

Website

https://www.immucell.com

ImmuCell Corp is engaged in the healthcare sector. The company operates in the development, acquisition, manufacture, and sale of products that improve the health and productivity of cows for the dairy and beef industries. The firm has developed products that provide immediate immunity to newborn dairy and beef cattle and is developing product line extensions of its existing products that address mastitis. Its lead product, First Defense, is manufactured to prevent scours in newborn calves. It has two segments Scours and Mastitis. The company generates the majority of its revenue from the United States.

Executives

Bryan K. Gathagan	director	56 EVERGREEN DRIVE, PORTLAND ME 04103
David Cunningham	director	56 EVERGREEN DRIVE, PORTLAND ME 04103
Gloria F Basse	director	56 EVERGREEN DRIVE, PORTLAND ME 04103
David Scott Tomsche	director	56 EVERGREEN DRIVE, PORTLAND ME 04103
Steven T. Rosgen	director	C/O IMMUCELL CORPORATION, 56 EVERGREEN DR., PORTLAND ME 04103
Norman H Pessin	other: See Explanation of Responses	C/O LEVY, HARKINS & CO., INC., 366 MADISON AVENUE, 14TH FLOOR, NEW YORK NY 10017
Brian L. Pessin	other: See Explanation of Responses	310 EAST 75TH STREET, APT. 2A, NEW YORK NY 10021
Joseph H Crabb	director, officer: Vice President and CSO	IMMUCELL CORP, 56 EVERGREEN DRIVE, PORTLAND ME 04103
Elizabeth Luttrell Williams	officer: Vice Pres. of Mfg Operations	C/O IMMUCELL CORPORATION, 56 EVERGREEN DRIVE, PORTLAND ME 04103
Jonathan E Rothschild	director, 10 percent owner	C/O IMMUCELL CORP, 56 EVERGREEN DRIVE, PORTLAND ME 04103
Linda Rhodes	director	56 EVERGREEN DRIVE, PORTLAND ME 04103
Paul R Wainman	director	56 EVERGREEN DRIVE, PORTLAND ME 04103
Michael F Brigham	director, officer: President and CEO	IMMUCELL CORP, 56 EVERGREEN DRIVE, PORTLAND ME 04103
Bobbi Jo Kunde	other: Director of Sales and Marketin	56 EVERGREEN DRIVE, PORTLAND ME 04103
Robert C Bruce	director	56 EVERGREEN DRIVE, PORTLAND ME 04103